Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorunicampOzelo, Margareth Castro-
dc.typeOutro documentopt_BR
dc.titleAhead international and german studies: 6-year interim effectiveness and safety outcomes in patients with hemophilia a receiving antihemophilic factor (recombinant) in a real-world settingpt_BR
dc.contributor.authorOldenburg, J.-
dc.contributor.authorOzelo, M. C.-
dc.contributor.authorKlamroth, R.-
dc.contributor.authorGuillet, B.-
dc.contributor.authorHuth-Kuehne, A.-
dc.contributor.authorKurnik, K.-
dc.contributor.authorKhair, K.-
dc.contributor.authorTsakiris, D. A.-
dc.contributor.authorBotha, J.-
dc.contributor.authorFernandez, A.-
dc.contributor.authorRegensburger, S.-
dc.contributor.authorTang, L.-
dc.contributor.authorSantagostino, E.-
dc.description.abstractThe international (INT) and German (GER) Antihemophilic factor (recombinant) (rAHF) Hemophilia A (HA) outcome Database (AHEAD) studies were designed to assess long‐term, real‐world outcomes in patients with moderate/severe HA receiving rAHF (ADVATE®, Baxalta US Inc, a Takeda company, Lexington, MA, USA). These 2 non‐interventional, prospective, long‐term, multicenter studies (INT: NCT02078427; GER: DRKS 00000556) include patients receiving prophylaxis (PRO) or on‐demand (OD) rAHF treatment. Key outcomes include annualized bleeding rates (ABRs) by disease severity (moderate – INT study: factor VIII [FVIII] level ≥1% to ≤5%; GER study: FVIII level ≥1% to <5%; or severe – FVIII <1% in both studies), and adverse events (AEs). Results of the 6‐year interim analysis are reported here (data cut‐off 15 July 2019). ABRs are listed as median (min–max). The INT study safety analysis set (SAS) comprised 707 patients (208 with moderate HA, 497 with severe HA); 579 patients received rAHF PRO and 111 patients rAHF OD. The GER study SAS comprised 382 patients (72 with moderate HA, 310 with severe HA); 303 patients received rAHF PRO and 74 patients rAHF OD. In the INT study, ABRs at year 1 in moderate HA patients were: PRO 1.0 (0.0–28.7), OD 1.8 (0.0–61.1); and in severe HA patients: PRO 1.8 (0.0–21.3), OD 6.3 (0.0–61.0). At year 6, ABRs in moderate HA patients were: PRO 0.0 (0.0–15.9), OD 0.0 (0.0–13.2); and in severe HA patients: PRO 0.0 (0.0–9.2), OD 2.7 (2.1–37.1). In the GER study, ABRs at year 1 in moderate HA patients were: PRO 0.0 (0.0–37.0), OD 6.0 (0.0–16.0); and in severe HA patients: PRO 2.2 (0.0–45.0), OD 33.0 (33.0–33.0). At year 6, ABRs in moderate HA patients were: PRO 2.0 (0.0–17.0), OD 2.3 (1.0–9.0); and in severe HA patients: PRO 4.5 (0.0–23.0), OD 0.0 (0.0–3.0). Any AEs were reported in 406/701 (57.9%) INT and 308/382 (80.6%) GER patients, including de novo inhibitors in 10 INT and 9 GER patients.These data show long‐term effectiveness and tolerability of rAHF regardless of disease severity in INT and GER study populations in a real‐world settingpt_BR
dc.publisher.countryReino Unidopt_BR
dc.description.issuespecial13th Annual Congress of European Association for Haemophilia and Allied Disorders 2020, 5–7 February 2020, The Hague, The Netherlandspt_BR
dc.description.provenanceSubmitted by Susilene Barbosa da Silva ( on 2021-03-10T15:27:20Z No. of bitstreams: 0. Added 1 bitstream(s) on 2021-07-07T17:16:58Z : No. of bitstreams: 1 000509655000142.pdf: 286408 bytes, checksum: debfd1e7939e2f0213b2a30fc3a5c72f (MD5)en
dc.description.provenanceMade available in DSpace on 2021-03-10T15:27:20Z (GMT). No. of bitstreams: 0 Previous issue date: 2020en
dc.contributor.departmentDepartamento de Clínica Médicapt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.subject.keywordAntihemophilic factorpt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000509655000142.pdf279.7 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.